Insights & Innovators

CEA-Framework-683x1024
ICER

Should ICER Be NICE (or Not)?: A Prelude to Our ISPOR Glasgow Issue Panel

ISPOR’s 20th Annual European Congress in Glasgow is fast approaching, with the first plenary session scheduled for this Monday, November 6th. I will be attending as part of BHE’s team and am looking forward to the plenary sessions discussing the evolution of value in healthcare, including the increase in value-based care initiatives, the future of[…]

Drug Pricing

Policy Corner: The Mysterious World of Drug Pricing

Almost every day, I see unflattering news stories regarding drug pricing and the cost of pharmaceuticals. Whether it's a supplier raising the costs of essential drugs like the Epi-Pen several-fold or a new CAR-T drug priced at a seemingly exorbitant rate - not unlike a three-bedroom house here in the Boston area - media and government scrutiny is[…]

TracyLiCancerQuote-300x150
Research and Publications

Real-World Evidence Study Published in the Journal Cancer Reveals a Five-Fold Cost Increase Associated With Metastatic Prostate Cancer

Researchers at Boston Health Economics, the Carolina Urologic Research Center, and Janssen, also found high hospitalization rates associated with metastatic prostate cancer. WALTHAM, MA, September 15, 2017 –—A new real-world evidence study shows that the development of prostate cancer metastasis was associated with a five-fold increase in medical[…]

ICER

A Need for Alignment: How ICER's New Cost-Effectiveness Framework Compares with the Second Panel's Recommendations

Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in[…]

ICER

Big Changes for HEOR in 2017

As we make our way through the first quarter of 2017, there are a lot of exciting changes happening in the field of health economics and outcomes research (HEOR) that may have important implications for how researchers generate and disseminate evidence.

ICER-Cost-Effectiveness-Ratio-683x1024
ICER

ICER's New Cost-Effectiveness Threshold Raises 5 Major Questions

Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should[…]

RWE & RWD

2016 Industry Insights: RWE and Centers of Excellence (CoE) Teams Growing

At BHE, we spend a lot of time speaking with leaders in the field of real world data about the ways in which they go about generating robust, reliable evidence for use with key stakeholders both internally and externally.  Fundamentally, the unique way that companies combine database experts, processes, and technology provides the best indication[…]

Instant Health Data

Put reliable, rapid analytics in the hands of more people across your organization

Learn more about Panalgo

Get the story behind our work and our team.